Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: Identification of a gene expression signature of poor prognosis

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3763-3771

  Lévy, Pascale ^a   Bièche, Ivan ^a,b   Leroy, Karen ^c   Parfait, Béatrice ^a   Wechsler, Janine ^c   Laurendeau, Ingrid ^a   Wolkenstein, Pierre ^c   Vidaud, Michel ^a   Vidaud, Dominique ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLT4 VEGFR3 GENE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GLI1 GENE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; MMP9 GENE; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1 ASSOCIATED PLEXIFORM NEUROFIBROMA; PATHOGENESIS; PERIPHERAL NERVE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHH GENE; SIGNAL TRANSDUCTION; TNFRSF10B TRAILR2 GENE; UPREGULATION;

ADOLESCENT; ADULT; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; NERVE SHEATH NEOPLASMS; NEUROFIBROMA; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; PHYLOGENY; POLYMERASE CHAIN REACTION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 2542524778     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0712     Document Type: Article

References (38)

1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6.
2. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point. Cell 1990;62:193-201.
3. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1. Science 1990;249:181-6.
4. Dasgupta B, Gutmann DH. Neurofibromatosis 1: closing the GAP between mice and men. Curr Opin Genet Dev 2003;13:20-7.
5. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992;69:265-73.
6. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-5.
7. Xu W, Mulligan LM, Ponder MA, et al. Loss of NF1 alleles in phaeochromocytomas from patients with type 1 neurofibromatosis. Genes Chromosomes Cancer 1992;4:337-42.
8. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993;3:122-6.
9. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995;11:90-2.
10. Sawada S, Florell S, Purandare SM, Ota M, Stephens K, Viskochil D. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 1996;14:110-2.
11. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001;104:593-604.
12. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62:1573-7.
13. Riccardi VM. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, Second Edition Baltimore and London: The Johns Hopkins University Press. 1992.
14. Scheithauer BW, Woodruff JM, Erlandson RA. Tumors of the Peripheral Nervous System. Washington, DC: Armed Forces Institute of Pathology: Atlas of Tumor Pathology. Third Series, Fascicle 24. 1999.
15. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-2.
16. Leroy K, Dumas V, Martin-Garcia N, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. Arch Dermatol 2001;137:908-13.
17. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-56.
18. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001;61:1652-8.
19. Kruskal WH, Wallis WA. Use of ranks on one-criterion variance analysis. J Am Stat Assoc 1952;47:583-621.
20. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
22. Didier G, Brezellec P, Remy E, Henaut A. GeneANOVA-gene expression analysis of variance. Bioinformatics 2002;18:490-1.
23. Romesburg CH. Cluster Analysis for Researchers. Belmont: Lifetime Learning Publications, 1984. p. 334.
24. Paradis V, Bièche I, Dargère D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003;163:733-41.
25. Mirsky R, Jessen KR. The neurobiology of Schwann cells. Brain Pathol 1999;2:293-311.
26. Kindblom LG, Ahlden M, Meis-Kindblom JM, Stenman G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch 1995;427:19-26.
27. Serra E, Rosenbaum T, Winner U, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000;9:3055-64.
28. O'Donovan N, Galvin M, Morgan JG. Physical mapping of the CXC chemokine locus on human chromosome 4. Cytogenet Cell Genet 1999;84:39-42.
29. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401-12.
30. Zorick TS, Lemke G. Schwann cell differentiation. Curr Opin Cell Biol., 1996 1996;8:870-6.
31. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
32. Lein M, Jung K, Ortel B, et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002;21:2089-96.
33. Packer RJ, Gutmann DH, Rubenstein A, et al. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002;58:1461-70.
34. Endo H, Utani A, Matsumoto F, et al. possible paracrine hedgehog signalling pathway in neurofibromas from patients with neurofibromatosis type 1. Br J Dermatol 2003;148:337-41.
35. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000;275:28341-4.
36. Yoon JW, Kita Y, Frank DJ, et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002;277:5548-55.
37. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002;2:361-72.
38. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-61.